TL;DR
This study reveals that low-dose ganciclovir (GCV), an antiviral drug, can effectively treat ulcerative colitis (UC) in mice by suppressing the STING signaling pathway in macrophages. This finding suggests a potential new therapeutic strategy for UC by repurposing an existing drug.
What Problem Does This Paper Address?
Inflammatory bowel disease (IBD), particularly ulcerative colitis (UC), is a chronic and debilitating condition affecting millions worldwide. Current treatments, while helpful, have limitations and side effects. The exact mechanisms driving UC are complex, involving genetic, environmental, and immune system dysregulation. Recent research has implicated the cGAS-STING pathway, a key component of the innate immune system, in various inflammatory conditions, including IBD. However, whether this pathway plays a direct role in UC pathogenesis and if it can be therapeutically targeted remains an open question. This paper investigates the potential of ganciclovir (GCV), an antiviral drug with known anti-inflammatory properties, to treat DSS-induced UC by modulating the cGAS-STING pathway.
Methods
The researchers employed a multi-pronged approach:
- In vitro studies: They used RAW264.7 macrophage cell lines to investigate the direct effects of GCV on the cGAS-STING pathway. This involved treating cells with varying concentrations of GCV and then stimulating them with lipopolysaccharide (LPS) or specific STING agonists (CMA, DMXAA, cGAMP). Gene and protein expression levels of key cGAS-STING pathway components were analyzed using quantitative real-time PCR (q-RT-PCR) and Western blotting.
- In vivo studies (animal models):
- DSS-induced colitis model: Mice were treated with dextran sulfate sodium (DSS) to induce acute and chronic colitis, mimicking human UC. Different doses of GCV were administered to assess therapeutic effects.
- STING-deficient mice: To specifically investigate the role of STING, the researchers used genetically modified mice lacking the STING gene (STINGgt/gt) and compared their response to DSS-induced colitis with wild-type (WT) mice.
- Assessment of disease severity: Various parameters were measured, including body weight loss, disease activity index (DAI), abdominal mechanical pain sensitivity, colon length, and histological injury scores.
- Gut microbiota analysis: 16S rRNA sequencing was performed on fecal samples to assess changes in the gut microbiome composition in different experimental groups.
- Human data analysis: Gene expression data from IBD patients (UC and Crohn's disease) was analyzed to confirm the upregulation of the cGAS-STING pathway in human disease. Immunohistochemistry was also used to examine STING expression in colon tissue samples from UC patients.
Datasets
- Publicly available IBD gene expression datasets: A meta-analysis of six published IBD studies based on microarrays was conducted.
- Human colon tissue samples: Samples from UC patients and adjacent normal colon cancer tissues were used for immunohistochemistry.
- Mouse models: Wild-type C57BL/6J mice and STING-deficient mice (STINGgt/gt) were used.
Key Insights and Ideas
- GCV's dual role: GCV exhibits a dose-dependent effect on the STING pathway. While high doses activate it, low doses (specifically 50 µM in vitro and 10 mg/kg/day in vivo) inhibit it. This is a crucial distinction for therapeutic application.
- STING pathway is a key player in UC: The study provides strong evidence that the cGAS-STING pathway is not only upregulated in DSS-induced colitis in mice but also in human UC and Crohn's disease patients. This highlights STING as a potential therapeutic target.
- STING deficiency confers protection: Mice lacking STING are significantly protected from DSS-induced colitis, showing reduced disease severity, less pain, and improved gut barrier function. This directly implicates STING in the pathogenesis of UC.
- GCV's therapeutic effect is STING-dependent: Crucially, GCV lost its therapeutic effect in STING-deficient mice, strongly suggesting that GCV's beneficial action in UC is mediated through its inhibition of STING signaling.
- Gut dysbiosis is linked to STING: STING deficiency also appears to mitigate the gut dysbiosis induced by DSS, suggesting a broader role for STING in maintaining gut microbial balance.
Key Results
- Low-dose GCV (50 µM) inhibited cGAS-STING pathway activation in RAW264.7 cells, reducing the expression of key inflammatory genes.
- The cGAS-STING pathway was significantly upregulated in the colons of DSS-induced colitis mice and in colon tissues of UC patients.
- Low-dose GCV (10 mg/kg/day) significantly ameliorated DSS-induced colitis in mice, reducing weight loss, DAI scores, and abdominal pain.
- GCV treatment significantly inhibited the upregulation of cGAS-STING pathway components in the colons of DSS-induced colitis mice.
- STING-deficient mice showed significantly reduced severity of DSS-induced colitis compared to WT mice.
- GCV treatment had no therapeutic effect on DSS-induced colitis in STING-deficient mice.
- 16S rRNA sequencing revealed that STING deficiency attenuated DSS-induced gut dysbiosis.
Limitations and Future Work
The authors acknowledge several limitations:
- Sex bias: The study exclusively used male mice. Given that IBD can exhibit sex-based differences in clinical presentation and severity, future studies should incorporate female mice.
- Dose-response curve: While low-dose GCV was identified as effective, a more detailed dose-response curve for GCV in the context of DSS-induced colitis would be beneficial.
- Role of gut microbiota: The study identified changes in gut microbiota but did not fully evaluate their role in GCV's therapeutic effects. Further research is needed to elucidate this complex interplay.
The authors suggest that repurposing GCV for UC treatment warrants further investigation, especially considering its FDA approval and potential to target the STING pathway.
Summary updated